The characterisation of gliomas using human monoclonal antibodies. Minireview on cancer research.
Malignant gliomas contain large numbers of invading lymphocytes. The function of these lymphocytes is unknown. It is likely that they are involved in host defence against the developing tumour. By isolating these cells and fusing them with a suitable myeloma system, hybrids can be established and their antibody activity analysed. Human monoclonal antibodies reactive to glioma cells have now been isolated and their specificity has been determined by radioimmunoassay, binding assays and immunoprecipitation. Furthermore, such antibodies can be radiolabelled with 131I and administered intravenously to localise tumours in patients. These antibodies have therapeutic potential as selective targeting agents for chemotherapy and other cytotoxic agents.